Evidence map›Paper›PMID 27774271›Full record

ArticleESC heart failure2016

Circulating biomarker responses to medical management vs. mechanical circulatory support in severe inotrope-dependent acute heart failure.

Anna J Meredith, Darlene L Y Dai, Virginia Chen, Zsuzsanna Hollander, Raymond Ng, Annemarie Kaan, Scott Tebbutt, Krishnan Ramanathan, Anson Cheung, Bruce M McManus

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Foreword.Cardiac failure review · 2017
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Anna J MeredithDepartment of Pathology and Laboratory MedicineUniversity of British ColumbiaVancouverCanada; PROOF Centre of ExcellenceVancouverCanada.ORCID 0000-0003-1596-2387
Darlene L Y DaiPROOF Centre of Excellence Vancouver Canada.
Virginia ChenPROOF Centre of Excellence Vancouver Canada.
Zsuzsanna HollanderPROOF Centre of Excellence Vancouver Canada.
Raymond NgPROOF Centre of ExcellenceVancouverCanada; Department of Computer ScienceUniversity of British ColumbiaVancouverCanada.
Annemarie KaanSchool of Nursing University of British Columbia - Heart Centre at St Paul's Hospital Vancouver Canada.
Scott TebbuttPROOF Centre of ExcellenceVancouverCanada; Department of MedicineUniversity of British ColumbiaVancouverCanada.
Krishnan RamanathanDivision of Cardiology University of British Columbia Vancouver Canada.
Anson CheungDivision of Surgery University of British Columbia Vancouver Canada.
Bruce M McManusDepartment of Pathology and Laboratory MedicineUniversity of British ColumbiaVancouverCanada; PROOF Centre of ExcellenceVancouverCanada.
University of British Columbia · CAPrevention of Organ Failure · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere inotrope-dependent acute heart failure (AHF) is associated with poor clinical outcomes. There are currently no well-defined blood biomarkers of response to treatment that can guide management or identify recovery in this patient population. In the present study, we characterized the levels of novel and emerging circulating biomarkers of heart failure in patients with AHF over the first 30 days of medical management or mechanical circulatory support (MCS). We hypothesized a shared a plasma proteomic treatment response would be identifiable in both patient groups, representing reversal of the AHF phenotype. METHODS AND

resultsTime course plasma samples of the first 30 days of therapy, obtained from patients managed medically (

conclusionsWe have characterized the temporal proteomic signature of clinical recovery in AHF patients managed medically or with MCS, over the first 30 days of treatment. Changes in biomarker expression over the time course of treatment may provide a basis for understanding the biological basis of AHF, potentially identifying novel markers and pathophysiologic mechanisms of recovery.

Indexed as

Acute heart failureBioinformaticsBiomarkersMechanical circulatory supportPlasma proteomicsVentricular assist device

Identifiers

PMID27774271
PMCPMC5063158
OpenAlexW2274731345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.